Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.12.015
Abstract: IMPORTANCE The identification of anaplastic lymphoma kinase (ALK) rearrangements in 2-5% of non-small cell lung cancer (NSCLC) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (TKI). Crizotinib was the first… read more here.
Keywords: medicine; alk; nsclc patients; treatment ... See more keywords
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.03.005
Abstract: OBJECTIVE In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQOL) outcomes from ALTA-1 L. MATERIALS AND METHODS HRQOL was… read more here.
Keywords: alk; crizotinib; brigatinib; lung cancer ... See more keywords
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.9022
Abstract: 9022Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naive ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Japanese patients randomiz... read more here.
Keywords: alk nsclc; alk; alk inhibitor; study ... See more keywords